Cargando…

Incorporating Target Shedding Into a Minimal PBPK–TMDD Model for Monoclonal Antibodies

Shedding of a pharmacological target from cells, giving rise to a soluble target that can also bind therapeutic proteins, is a common phenomenon. In this study, a minimal physiologically based pharmacokinetic model was used to simulate the pharmacokinetics of trastuzumab and the simultaneous binding...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, L, Gardner, I, Rose, R, Jamei, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910015/ https://www.ncbi.nlm.nih.gov/pubmed/24477089 http://dx.doi.org/10.1038/psp.2013.73

Ejemplares similares

A Tutorial on Target-Mediated Drug Disposition (TMDD) Models
por: Dua, P, et al.
Publicado: (2015)

Occurrence and temporal variations of TMDD in the river Rhine, Germany
por: Guedez, Arlen A., et al.
Publicado: (2009)

Where Do PBPK Models Stand in Pharmacometrics and Systems Pharmacology?
por: Jamei, Masoud
Publicado: (2020)

Development of a Multicompartment Permeability-Limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis Drugs
por: Gaohua, L, et al.
Publicado: (2015)

Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance
por: Jamei, Masoud
Publicado: (2016)

Minimal brain PBPK model to support the preclinical and clinical development of antibody therapeutics for CNS diseases
por: Bloomingdale, Peter, et al.
Publicado: (2021)

Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model
por: Chetty, Manoranjenni, et al.
Publicado: (2015)

Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability
por: Chetty, Manoranjenni, et al.
Publicado: (2014)

Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model
por: Kuepfer, L, et al.
Publicado: (2016)

Mechanistic PBPK Modelling to Predict the Advantage of the Salt Form of a Drug When Dosed with Acid Reducing Agents
por: Chirumamilla, Siri Kalyan, et al.
Publicado: (2021)

Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment—A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model
por: Ternant, David, et al.
Publicado: (2021)

Population PBPK modeling using parametric and nonparametric methods of the Simcyp Simulator, and Bayesian samplers
por: Wedagedera, Janak R., et al.
Publicado: (2022)

Evaluation of an In Silico PBPK Post-Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine
por: Darwich, A S, et al.
Publicado: (2013)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz
por: Chetty, Manoranjenni, et al.
Publicado: (2018)

ATLAS mPBPK: A MATLAB‐Based Tool for Modeling and Simulation of Minimal Physiologically‐Based Pharmacokinetic Models
por: Mavroudis, Panteleimon D., et al.
Publicado: (2019)

Pharmacokinetic Characterization and Tissue Distribution of Fusion Protein Therapeutics by Orthogonal Bioanalytical Assays and Minimal PBPK Modeling
por: Sugimoto, Hiroshi, et al.
Publicado: (2020)

Experimental Data and PBPK Modeling Quantify Antibody Interference in PEGylated Drug Carrier Delivery
por: Talkington, Anne M., et al.
Publicado: (2021)

PBPK-PD modeling for the preclinical development and clinical translation of tau antibodies for Alzheimer’s disease
por: Bloomingdale, Peter, et al.
Publicado: (2022)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK
por: Wagner, C, et al.
Publicado: (2015)

PBPK modeling and simulation in drug research and development
por: Zhuang, Xiaomei, et al.
Publicado: (2016)

Guide to development of compound files for PBPK modeling in the Simcyp population‐based simulator
por: Ezuruike, Udoamaka, et al.
Publicado: (2022)

Novel Mechanistic PBPK Model to Predict Renal Clearance in Varying Stages of CKD by Incorporating Tubular Adaptation and Dynamic Passive Reabsorption
por: Huang, Weize, et al.
Publicado: (2020)

Complex Mixtures: Array PBPK Modeling of Jet Fuel Components
por: Sterner, Teresa R., et al.
Publicado: (2023)

A Workflow for Global Sensitivity Analysis of PBPK Models
por: McNally, Kevin, et al.
Publicado: (2011)

PBPK Modeling on Organs-on-Chips: An Overview of Recent Advancements
por: Yang, Yi, et al.
Publicado: (2022)

Permeability of Gemcitabine and PBPK Modeling to Assess Oral Administration
por: Ferreira, Abigail, et al.
Publicado: (2021)

PBPK Model for Atrazine and Its Chlorotriazine Metabolites in Rat and Human
por: Campbell, Jerry L., et al.
Publicado: (2016)

Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma
por: Vassilakopoulos, Theodoros P., et al.
Publicado: (2023)

Current PBPK Models: Are They Predicting Tissue Drug Concentration Correctly?
por: Ibarra, Manuel, et al.
Publicado: (2020)

PBPK model reporting template for chemical risk assessment applications
por: Tan, Yu-Mei, et al.
Publicado: (2020)

PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease
por: Montanha, Maiara Camotti, et al.
Publicado: (2022)

PKQuest: PBPK modeling of highly lipid soluble and extracellular solutes
por: Levitt, David G.
Publicado: (2018)

Approaches to developing alternative and predictive toxicology based on PBPK/PD and QSAR modeling.
por: Yang, R S, et al.
Publicado: (1998)

Minimal Physiologically-Based Pharmacokinetic (mPBPK) Metamodeling of Target Engagement in Skin Informs Anti-IL17A Drug Development in Psoriasis
por: Ayyar, Vivaswath S., et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Metabolic Pathways of Bromochloromethane in Rats
por: Cuello, W. S., et al.
Publicado: (2012)

Drug-targeting by monoclonal antibodies.
por: Embleton, M. J.
Publicado: (1987)

Quality Assurance of PBPK Modeling Platforms and Guidance on Building, Evaluating, Verifying and Applying PBPK Models Prudently under the Umbrella of Qualification: Why, When, What, How and By Whom?
por: Frechen, Sebastian, et al.
Publicado: (2022)

Redistribution and shedding of flagellar membrane glycoproteins visualized using an anti-carbohydrate monoclonal antibody and concanavalin A
Publicado: (1986)

Analysis of biomarker utility using a PBPK/PD model for carbaryl
por: Phillips, Martin B., et al.
Publicado: (2014)

Statistical analysis of Fisher et al. PBPK model of trichloroethylene kinetics.
por: Bois, F Y
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_ktb367v922bmmj5r6uhjk2mijl